Pfizer’s Herceptin biosimilar wins FDA nod

Mar 11, 2019

This week, the FDA approved Pfizer’s Herceptin copycat, Trazimera, nearly a year after it red-lighted the drug and requested additional technical information. 

Herceptin, which raked in nearly $3 billion in sales last year, is already facing biosimilar competition from Mylan, Celltrion and Samsung. Sales of Herceptin have been particularly battered by biosimilars in Europe. 

Roche is now reportedly putting more focus on another breast cancer treatment, Kadcyla, to help offset lost sales from Herceptin competition. 

Read the full Reuters report.

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments